Skip to search formSkip to main contentSkip to account menu

NCX1000

Known as: NCX 1000, NCX-1000 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
OBJECTIVES:NCX-1000 (2(acetyloxy) benzoic acid-3(nitrooxymethyl)phenyl ester) is an nitric oxide (NO)-releasing derivative of… 
Review
2008
Review
2008
EDITORIAL EXPRESSION OF CONCERN. PNAS is publishing an Editorial Expression of Concern regarding the following three articles: (i… 
2007
2007
Nonalcoholic steatohepatitis (NASH) is a common and potentially severe form of liver disease. This study aimed to determine the… 
2004
2004
NCX‐1000, (3α, 5β, 7β)‐3,7‐dihydroxycholan‐24oic acid[2‐methoxy‐4‐[3‐[4‐(nitroxy)butoxy]‐3‐oxo‐1‐propenyl]phenyl ester, is a… 
Review
2004
Review
2004
Portal hypertension, a life threatening complication of liver cirrhosis, results from increased intrahepatic resistance and… 
Highly Cited
2001
Highly Cited
2001
Portal hypertension resulting from increased intrahepatic resistance is a common complication of chronic liver diseases and a… 
Highly Cited
2001
Highly Cited
2001
Caspases are key mediators in liver inflammation and apoptosis. In the present study we provide evidence that a nitric oxide (NO…